Regulatory Reporting After Site Close-Out Visits in Clinical Trials
Regulatory Reporting Requirements After Site Close-Out Visits Once a clinical trial site completes all subject-related activities and the final investigational product (IP) reconciliation, the next critical step is regulatory reporting. This phase ensures that all necessary documentation and notifications are submitted to the appropriate authorities, institutional ethics committees, and trial sponsors to confirm site closure….
Read More “Regulatory Reporting After Site Close-Out Visits in Clinical Trials” »